Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
Identifieur interne : 002F85 ( PubMed/Checkpoint ); précédent : 002F84; suivant : 002F86Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
Auteurs : Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann ; Michael S. OkunSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antipsychotic Agents (adverse effects), Brief Psychiatric Rating Scale, Clozapine (adverse effects), Dibenzothiazepines (adverse effects), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Tolerance, Female, Humans, Male, Parkinson Disease (complications), Prospective Studies, Psychotic Disorders (complications), Psychotic Disorders (drug therapy), Recurrence, Time Factors.
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Clozapine, Dibenzothiazepines.
- complications : Parkinson Disease, Psychotic Disorders.
- drug therapy : Psychotic Disorders.
- Aged, Aged, 80 and over, Brief Psychiatric Rating Scale, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Tolerance, Female, Humans, Male, Prospective Studies, Recurrence, Time Factors.
Abstract
To determine whether psychiatrically stable patients with a history of drug-induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on-going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses.
DOI: 10.1002/mds.20260
PubMed: 15390047
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15390047Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610, USA. fernandez@neurology.ufl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610</wicri:regionArea><wicri:noRegion>Florida 32610</wicri:noRegion></affiliation></author><author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E" last="Trieschmann">Martha E. Trieschmann</name></author><author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15390047</idno><idno type="pmid">15390047</idno><idno type="doi">10.1002/mds.20260</idno><idno type="wicri:Area/PubMed/Corpus">003266</idno><idno type="wicri:Area/PubMed/Curation">003266</idno><idno type="wicri:Area/PubMed/Checkpoint">002F85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610, USA. fernandez@neurology.ufl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610</wicri:regionArea><wicri:noRegion>Florida 32610</wicri:noRegion></affiliation></author><author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E" last="Trieschmann">Martha E. Trieschmann</name></author><author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antipsychotic Agents (adverse effects)</term><term>Brief Psychiatric Rating Scale</term><term>Clozapine (adverse effects)</term><term>Dibenzothiazepines (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Tolerance</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease (complications)</term><term>Prospective Studies</term><term>Psychotic Disorders (complications)</term><term>Psychotic Disorders (drug therapy)</term><term>Recurrence</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term><term>Dibenzothiazepines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Brief Psychiatric Rating Scale</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Tolerance</term><term>Female</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Recurrence</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine whether psychiatrically stable patients with a history of drug-induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on-going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15390047</PMID><DateCreated><Year>2005</Year><Month>01</Month><Day>24</Day></DateCreated><DateCompleted><Year>2005</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>104-5</MedlinePgn></Pagination><Abstract><AbstractText>To determine whether psychiatrically stable patients with a history of drug-induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on-going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses.</AbstractText><CopyrightInformation>(c) 2004 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610, USA. fernandez@neurology.ufl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trieschmann</LastName><ForeName>Martha E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Okun</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>BGL0JSY5SI</RegistryNumber><NameOfSubstance UI="C069541">quetiapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2005 Apr;20(4):515; author reply 515</RefSource><PMID Version="1">15747367</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010054">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003987">Dibenzothiazepines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004361">Drug Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15390047</ArticleId><ArticleId IdType="doi">10.1002/mds.20260</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E" last="Trieschmann">Martha E. Trieschmann</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002F85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15390047
|texte= Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15390047" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |